Aflibercept FDA approval date

The FDA approved Aflibercept (Eylea) on 18 Nov 2011.

FDA approval date
18 Nov 2011

Drug identity checked against registry records

Also recorded as Eylea

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)NCT04592419KODPhase 3Completed2022-06-10Actual
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.NCT04049266KODPhase 2, Phase 3Terminated2021-11-17Actual
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04611152KODPhase 3Terminated2023-05-11Actual
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKNCT06556368KODPhase 3Active not recruiting2026-09-02Actual
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)NCT04603937KODPhase 3Terminated2023-04-27Actual
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular DegenerationNCT06223958OCULPhase 3Active not recruiting2026-04-29Estimated
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)NCT04964089KODPhase 3Completed2023-03-28Actual
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationNCT06495918OCULPhase 3Active not recruiting2027-01-08Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2011-11-18DayAfliberceptFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA125387", "applicant_as_listed_by_fda": "REGENERON PHARMACEUTICALS", "brand_names": ["EYLEA"], "active_ingredients": ["AFLIBERCEPT"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20111118", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026